SCHEMBL22925566

SCHEMBL22925566

O=C(NO)c1ncc(Nc2ncc(-c3ccc(C(F)(F)F)cc3)o2)cn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPV1 Q8NER1 10/20 0.47
▸ HDAC1 Q13547 3/20 0.47
▸ HDAC6 Q9UBN7 3/20 0.47
▸ ALOX5 P09917 1/20 0.45
▸ FLT1 P17948 2/20 0.43
▸ KDR P35968 2/20 0.43
▸ FLT4 P35916 1/20 0.43
▸ VCP P55072 2/20 0.43
▸ DGAT1 O75907 1/20 0.42
▸ PRKAB2 O43741 1/20 0.40
▸ LCK P06239 1/20 0.40
▸ SRC P12931 1/20 0.40
▸ FLT3 P36888 1/20 0.40
▸ PRKAG1 P54619 1/20 0.40
▸ PRKAA2 P54646 1/20 0.40
▸ PRKAA1 Q13131 1/20 0.40
▸ RPS6KA1 Q15418 1/20 0.40
▸ MKNK1 Q9BUB5 1/20 0.40
▸ PRKAG3 Q9UGI9 1/20 0.40
▸ PRKAG2 Q9UGJ0 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22925571 0.88 TRPV1 (0.49) TRPV1ALOX5FLT1KDRFLT4
SCHEMBL31013371 0.86 VCP (0.46) TRPV1HDAC1HDAC6ALOX5FLT1
SCHEMBL22925735 0.86 VCP (0.46) TRPV1HDAC1HDAC6ALOX5FLT1
SCHEMBL28733672 0.86 TRPV1 (0.50) TRPV1HDAC1HDAC6ALOX5FLT1
SCHEMBL22925569 0.85 TRPV1 (0.47) TRPV1HDAC1HDAC6ALOX5FLT1
SCHEMBL28733675 0.81 TRPV1 (0.47) TRPV1ALOX5FLT1KDRFLT4
SCHEMBL22925592 0.81 TRPV1 (0.47) TRPV1ALOX5FLT1KDRFLT4
SCHEMBL22925676 0.80 HSD11B1 (0.47) TRPV1HDAC1HDAC6HDAC3HDAC2
SCHEMBL22925576 0.79 TRPV1 (0.47) TRPV1ALOX5FLT1KDRFLT4
SCHEMBL22925659 0.79 TRPV1 (0.45) TRPV1HDAC1HDAC6KDRDGAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220274970-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2022-09-01 — — US disclosed
WO-2021012018-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2021-01-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220274970-A1 INHIBITOR COMPOUNDS SERPINB1, MMP1, SSB TRPV1 4690/4885HDAC1 19/4885HDAC6 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback